{"result": "(\"entity\"<|>HORMONAL TREATMENT<|>EVENT<|>Hormonal treatment for hypogonadism aims to induce and maintain virilization and normal sexual function, as well as promote psychological well-being.)\n##\n(\"entity\"<|>AGRESIVIDAD<|>EVENT<|>Agresividad is a potential adverse effect that may arise from testosterone treatment.)\n##\n(\"entity\"<|>GINECOMASTIA<|>EVENT<|>Ginecomastia is a condition that can occur as an adverse effect of testosterone treatment, characterized by the enlargement of breast tissue in males.)\n##\n(\"entity\"<|>ACNÉ<|>EVENT<|>Acné is another possible side effect of testosterone treatment, affecting the skin.)\n##\n(\"entity\"<|>GONADOTROFINAS<|>EVENT<|>Gonadotropinas are hormones that can be administered to stimulate spermatogenesis in patients with hypogonadismo hipogonadotropo.)\n##\n(\"entity\"<|>FSH<|>EVENT<|>FSH, or Follicle-Stimulating Hormone, is a gonadotropin that is elevated in primary hypogonadism.)\n##\n(\"entity\"<|>LH<|>EVENT<|>LH, or Luteinizing Hormone, is another gonadotropin that is elevated in primary hypogonadism.)\n##\n(\"relationship\"<|>TESTOSTERONE<|>AGRESIVIDAD<|>Testosterone treatment may lead to increased aggressiveness as a side effect<|>6)\n##\n(\"relationship\"<|>TESTOSTERONE<|>GINECOMASTIA<|>Testosterone treatment can cause ginecomastia as a side effect<|>6)\n##\n(\"relationship\"<|>TESTOSTERONE<|>ACNÉ<|>Testosterone treatment may result in acné as a side effect<|>6)\n##\n(\"relationship\"<|>GONADOTROFINAS<|>HIPOGONADISMO HIPOGONADOTROPO<|>Gonadotropinas are used to stimulate spermatogenesis in patients with hipogonadismo hipogonadotropo<|>7)\n##\n(\"relationship\"<|>FSH<|>HIPOGONADISMO HIPOGONADOTROPO<|>FSH levels are elevated in cases of primary hypogonadism<|>8)\n##\n(\"relationship\"<|>LH<|>HIPOGONADISMO HIPOGONADOTROPO<|>LH levels are elevated in cases of primary hypogonadism<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Por el mayor riesgo de desarrollar el síndrome metabólico (obesidad abdominal, hipertensión\n        • Kanakis GA, Nieschlag E. Klinefelter syndrome: more than hypogonadism. Metabolism. 2018;86:135-44.              arterial, dislipemia con descenso de colesterol HDL con hipertrigliceridemia e intolerancia hi-\n        • Snyder PJ. Causes of primary hypogonadism in males. Matsumoto AM, ed. UpToDate. Waltham, MA: UpToDate Inc.\n          https://www.uptodate.com (Last updated: Feb 06, 2018.)                                                          drocarbonada o diabetes mellitus) hay que valorar todos sus componentes.\n\n\n\n                                                                                                                          El aumento del hematocrito que puede seguir al tratamiento con testosterona puede sumarse\n        En un paciente varón de 35 años con un hipogonadismo hipogonadotropo en                                           al síndrome metabólico en la predisposición a eventos cardiovasculares, por lo que también\n     9                                                                                                                    es merecedor de seguimiento. Otros efectos adversos que deben vigilarse son el aumento de\n        tratamiento con testosterona intramuscular se recomiendan los siguientes                                          la agresividad, la ginecomastia o el acné.\n        controles, menos uno. Señálelo:                                                                                   En el hipogonadismo hipogonadotropo, la espermatogénesis puede ser estimulada admi-\n        A. Gonadotropinas.                                                                                                nistrando gonadotrofinas parenterales (2-3 veces por semana), lo que busca aumentar la\n        B. Testosterona.                                                                                                  secreción de testosterona testicular por las células de Leydig y la espermatogénesis trans-\n        C. Perfil lipídico.                                                                                               curridos unos meses de tratamiento.\n        D.  Hemograma.                                                                                                    También hay que plantear el tratamiento de las causas del hipogonadismo cuando sea posi-\n                                                                                                                          ble (funcionales, farmacológicas, tumorales).\n        COMENTARIO                                                                                                        Referencias:\n                                                                                                                          • Bhasin S, Yialamas MA, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, et al. Testosterone Therapy in Men With Hypogonadism:\n                                                                                                                            An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab [Internet]. 2018;103(5):1715-44. https://doi.org/10.1210/\n        El hipogonadismo se caracteriza por concentraciones en sangre bajas de testosterona y un                            jc.2018-00229\n        deterioro de la espermatogénesis. Si el hipogonadismo tiene un origen testicular (hipogona-                       • Boehm U, Bouloux P-M, Dattani MT, de Roux N, Dodé C, Dunkel L, et al. European Consensus Statement on congenital hypogonado-\n                                                                                                                            tropic hypogonadism—pathogenesis, diagnosis and treatment. Nat Rev Endocrinol [Internet]. 2015;11:547. https://doi.org/10.1038/\n        dismo primario) las gonadotrofinas (FSH y LH) estarán elevadas, y si es hipotálamo-hipofisa-                        nrendo.2015.112\n        rio (hipogonadismo secundario o hipogonadotropo) se encontrarán reducidas (o inadecuada-\n        mente normales).\n        El objetivo del tratamiento hormonal del hipogonadismo con testosterona es inducir y man-                     10  Una paciente diagnosticada de síndrome de Turner por talla baja es seguida en\n        tener la virilización y la función sexual normal, estimular el crecimiento natural cuando to-                     pediatría hasta que a los 15 años pasa a la unidad de endocrinología de adultos.\n        davía es posible, promover la salud ósea, el trofismo muscular y el bienestar psicológico y                       Con respecto al seguimiento de esta paciente, señale la respuesta falsa:\n        emocional. Este tratamiento no consigue la mejora de la espermatogénesis ni el crecimiento                        A. La alteración cardiovascular potencialmente más grave es la disección de aorta. Por ello\n        testicular, e incluso los empeora.                                                                                    hay que vigilar más estrechamente a los pacientes con dilatación en la aorta ascendente.\n        Para iniciar la androgenización en pacientes hipogonadales se utiliza testosterona en dosis                       B. La obesidad y la diabetes mellitus de tipo 2 son poco frecuentes en estos pacientes.\n        bajas (100-200 mg i.m. mensual, y después cada 2 a 3 semanas). Una vez inducida la an-                            C. El riesgo de sordera neurosensorial es alto en estas pacientes.\n        drogenización, se continúa con testosterona i.m. en sus formas de cipionato o propionato                          D.  Estas pacientes tienen mayor riesgo de osteoporosis y fracturas. En el seguimiento hay\n        (100-250 mg/2-4 semanas), undecanoato (1 g/10-14 semanas)\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>KANAKIS GA<|>PERSON<|>Kanakis GA is an author who contributed to the study of Klinefelter syndrome, focusing on its broader implications beyond hypogonadism.)\n##\n(\"entity\"<|>NIESCHLAG E<|>PERSON<|>Nieschlag E is a co-author of the study on Klinefelter syndrome, contributing to the understanding of its effects on metabolism.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc is a medical resource that provides clinical information, including causes of primary hypogonadism in males.)\n##\n(\"entity\"<|>MATSUMOTO AM<|>PERSON<|>Matsumoto AM is the editor of the UpToDate resource that discusses primary hypogonadism in males.)\n##\n(\"entity\"<|>TESTOSTERONE<|>EVENT<|>Testosterone is a hormone used in treatment for conditions like hypogonadism, with various effects and monitoring requirements.)\n##\n(\"entity\"<|>HIPOGONADISMO HIPOGONADOTROPO<|>EVENT<|>Hipogonadismo hipogonadotropo is a condition characterized by low testosterone levels and impaired spermatogenesis.)\n##\n(\"entity\"<|>SÍNDROME METABÓLICO<|>EVENT<|>Síndrome metabólico refers to a cluster of conditions that increase the risk of heart disease, stroke, and diabetes.)\n##\n(\"entity\"<|>SÍNDROME DE TURNER<|>EVENT<|>Síndrome de Turner is a genetic disorder affecting females, characterized by the absence of part or all of a second sex chromosome.)\n##\n(\"relationship\"<|>KANAKIS GA<|>NIESCHLAG E<|>Kanakis GA and Nieschlag E collaborated on research regarding Klinefelter syndrome<|>7)\n##\n(\"relationship\"<|>UPTODATE INC<|>MATSUMOTO AM<|>Matsumoto AM is the editor of UpToDate Inc, which provides information on primary hypogonadism<|>8)\n##\n(\"relationship\"<|>TESTOSTERONE<|>HIPOGONADISMO HIPOGONADOTROPO<|>Testosterone is used as a treatment for hipogonadismo hipogonadotropo<|>9)\n##\n(\"relationship\"<|>SÍNDROME METABÓLICO<|>TESTOSTERONE<|>Testosterone treatment can influence the components of síndrome metabólico<|>6)\n##\n(\"relationship\"<|>SÍNDROME DE TURNER<|>SÍNDROME METABÓLICO<|>Patients with síndrome de Turner may have an increased risk of developing síndrome metabólico<|>5)\n<|COMPLETE|>"}]}